Kim Blackwell, incoming CEO, Zentalis Pharmaceuticals

Pfiz­er-part­nered Zen­tal­is woos new CEO, cob­bles to­geth­er $200M

Ready to trans­form it­self in­to a se­ri­ous mid- to late-stage can­cer play­er that could take on ri­vals as big as As­traZeneca, a Pfiz­er-part­nered biotech is em­brac­ing some big changes.

Eli Lil­ly vet Kim Black­well is suc­ceed­ing An­tho­ny Sun as CEO of Zen­tal­is. Sun, a for­mer VC at Ais­ling who co-found­ed Zen­tal­is in 2015, will re­main at the helm of its Asia-fo­cused joint ven­ture, Zen­tera.

Black­well’s man­date will be to speed up the de­vel­op­ment of the two lead can­di­dates. Zen­tal­is has al­so raised $200 mil­lion from an un­der­writ­ten of­fer­ing that priced its stock at $19.38 per share.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.